CRISPR/Cas9-mediated gene disruption was employed to generate a polyclonal population of HeLa cells carrying a loss-of-function knockout of the EIF4H gene. This EIF4H Knockout HeLa Polyclonal Cells product provides a genetically heterogeneous pool of edited cells, enabling robust functional studies of EIF4H-dependent translation initiation without the clonal selection bias inherent to single-cell-derived lines. The pooled format maintains genetic diversity while effectively ablating EIF4H expression across the cell population, making it suitable for high-throughput screening and pooled phenotypic analyses.
HeLa cells are a well-established human cervical adenocarcinoma epithelial cell line, characterized by integrated human papillomavirus type 18 (HPV18) sequences that inactivate the tumor suppressors p53 and Rb. This immortalized cell line is a cornerstone of biomedical research, serving as a versatile model for cancer biology, signal transduction, and translational control studies. The transformed phenotype and robust growth properties of HeLa cells make them an ideal host for investigating the role of translation initiation factors in oncogenic processes.
EIF4H encodes a translation initiation factor that stimulates the ATP-dependent RNA helicase activity of EIF4A, facilitating the unwinding of stable secondary structures within the 5?? untranslated regions (UTRs) of mRNAs. Together with EIF4B and the EIF4F complex (comprising EIF4E, EIF4G, and EIF4A), EIF4H promotes 43S preinitiation complex scanning and efficient translation initiation, particularly of transcripts with highly structured 5?? UTRs, such as those encoding oncoproteins and growth regulators. EIF4H activity is regulated by the mTOR signaling pathway: growth factor stimulation activates mTOR, which phosphorylates downstream effectors like S6K and 4E-BP1, modulating EIF4F complex assembly and EIF4H function. Consequently, EIF4H operates as a node integrating growth signals with selective mRNA translation.
In the context of HeLa cells, which exhibit deregulated mTOR signaling and heightened cap-dependent translation, loss of EIF4H disrupts the translation of a subset of mRNAs critical for proliferation and survival. Given the reliance of cancer cells on enhanced translation of structured 5?? UTR-containing oncogenic transcripts, this knockout model provides a platform to dissect the specific contributions of EIF4H to oncogene expression, cell growth, and stress responses. The polyclonal nature of the population allows assessment of overall pathway dependency without the confounding effects of clonal adaptation.
This product is ideally suited for a wide range of functional assays, including western blotting to confirm loss of EIF4H protein, polysome profiling to evaluate global translation, dual-luciferase reporter assays with structured 5?? UTRs to measure helicase-dependent translation, and co-immunoprecipitation to examine interactions with EIF4A and EIF4B. It also enables phospho-mTOR signaling analysis and cell proliferation studies, supporting research into translation regulation, cancer cell biology, and therapeutic targeting of the translational machinery. For detailed technical specifications and ordering information, please contact Ascent Research.
